Benschop Laura, Farquhar Cindy, van der Poel Nicolien, Heineman Maas Jan
Department of Obstetrics & Gynaecology Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands.
Cochrane Database Syst Rev. 2010 Nov 10;2010(11):CD008571. doi: 10.1002/14651858.CD008571.pub2.
Endometriomata are cysts of endometriosis in the ovaries. As artificial reproductive technology (ART) cycles involve oocyte pickup from the ovaries, endometriomata may interfere with the outcome of ART.
To determine the effectiveness and safety of surgery, medical treatment, combination therapy or no treatment for improving reproductive outcomes among women with endometriomata, prior to undergoing ART cycles.
The review authors searched: Cochrane Menstrual Disorders and Subfertility Group Specialised Register of trials, CENTRAL (The Cochrane Library), EMBASE, MEDLINE, PubMed, PsycINFO, CINAHL, DARE, trial registers for ongoing and registered trials, citation indexes, conference abstracts on the ISI Web of Knowledge, Clinical Study Results, OpenSIGLE (July 2010) and handsearched Fertility and Sterility (2008 to 2010).
Randomised controlled trials of any medical, surgical or combination therapy or expectant management for endometriomata prior to ART.
The trials were independently identified and assessed for risk of bias by two authors. The authors of the trials that were potentially eligible for inclusion were contacted for additional information. Outcomes were expressed as Peto odds ratios and mean differences (MD).
Eleven trials were identified of which seven were excluded and four with 312 participants were included.No trial reported live birth outcomes. One trial compared gonadotropin-releasing hormone (GnRH) agonist with GnRH antagonist. There was no evidence of a difference for clinical pregnancy rate (CPR), however the number of mature oocytes retrieved (NMOR) was greater with GnRH agonists (MD -1.60, 95% CI -2.44 to -0.76) and the ovarian response was increased (estradiol (E2) levels on day of human chorionic gonadotropin (hCG) injection) (MD -456.30, 95% CI -896.06 to -16.54).Surgery (aspiration or cystectomy) versus expectant management (EM) showed no evidence of a benefit for clinical pregnancy with either technique. Aspiration was associated with greater NMOR (MD 0.50, 95% CI 0.02 to 0.98) and increased ovarian response (E2 levels on day of hCG injection) (MD 685.3, 95% CI 464.50 to 906.10) compared to EM.Cystectomy was associated with a decreased ovarian response to controlled ovarian hyperstimulation (COH) (MD -510.00, 95% CI -676.62 to -343.38); no evidence of an effect on the NMOR compared to EM. Aspiration versus cystectomy showed no evidence of a difference in CPR or the NMOR.
AUTHORS' CONCLUSIONS: There was no evidence of an effect on reproductive outcomes in any of the four included trials. Further RCTs of management of endometrioma in women undergoing ART are required.
子宫内膜瘤是卵巢子宫内膜异位症的囊肿。由于辅助生殖技术(ART)周期涉及从卵巢采集卵母细胞,子宫内膜瘤可能会干扰ART的结局。
确定在进行ART周期之前,手术、药物治疗、联合治疗或不治疗对改善患有子宫内膜瘤的女性生殖结局的有效性和安全性。
综述作者检索了:Cochrane月经紊乱与生育力低下小组专业试验注册库、CENTRAL(Cochrane图书馆)、EMBASE、MEDLINE、PubMed、PsycINFO、CINAHL、DARE、正在进行和已注册试验的试验注册库、引文索引、ISI知识网络上的会议摘要、临床研究结果、OpenSIGLE(2010年7月),并对手检了《生育与不孕》(2008年至2010年)。
ART之前对子宫内膜瘤进行任何药物、手术或联合治疗或期待治疗的随机对照试验。
由两位作者独立识别试验并评估偏倚风险。联系了可能符合纳入标准的试验的作者以获取更多信息。结果以Peto比值比和平均差(MD)表示。
共识别出11项试验,其中7项被排除,4项试验纳入了312名参与者。没有试验报告活产结局。一项试验比较了促性腺激素释放激素(GnRH)激动剂与GnRH拮抗剂。没有证据表明临床妊娠率(CPR)存在差异,然而,GnRH激动剂组回收的成熟卵母细胞数量(NMOR)更多(MD -1.60,95%CI -2.44至-0.76),并且卵巢反应增强(人绒毛膜促性腺激素(hCG)注射日的雌二醇(E2)水平)(MD -456.30,95%CI -896.06至-16.54)。手术(抽吸或囊肿切除术)与期待治疗(EM)相比,两种技术在临床妊娠方面均未显示出益处。与EM相比,抽吸与更多的NMOR(MD 0.50,95%CI 0.02至0.98)和增强的卵巢反应(hCG注射日的E2水平)(MD 685.3,95%CI 464.50至906.10)相关。囊肿切除术与对控制性卵巢过度刺激(COH)的卵巢反应降低相关(MD -510.00,95%CI -676.62至-343.38);与EM相比,对NMOR没有影响的证据。抽吸与囊肿切除术相比,在CPR或NMOR方面没有差异的证据。
纳入的四项试验中没有一项显示对生殖结局有影响。需要对接受ART的女性子宫内膜瘤管理进行进一步的随机对照试验。